Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Keita Inami"'
Publikováno v:
Biopharmaceutics & Drug Disposition. 36:139-147
The bioavailability of orally administered therapies are often significantly limited in the human intestine by the metabolic activities of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Predicting whether candidate compounds induce CYP3A4 an
Autor:
Shigeru Ohmori, Tamihide Matsunaga, Keita Inami, Masahiro Tohkin, Takamitsu Sasaki, Hitomi Sasaki, Yu Sato, Shogo Takahashi, Kiyoshi Nagata, Takeshi Kumagai, Masakiyo Hosokawa
Publikováno v:
Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences). 40:488-499
Autor:
Yoshihiro Numata, Keita Inami, Kodai Funakoshi, Satomi Matsui, Shuichi Kanno, Takamitsu Sasaki, Kiyoshi Nagata, Kouichi Yoshinari, Midori Yoshida, Takayoshi Toriyabe, Yasushi Yamazoe, Takeshi Kumagai
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 359(1)
Multidrug resistance-associated protein 3 (MRP3) is a basolaterally localized transporter in the liver and contributes to the transport of various metabolites such as conjugates of endogenous compounds and drugs from hepatocytes. MRP3 expression in t
Publikováno v:
Biopharmaceuticsdrug disposition. 36(3)
The bioavailability of orally administered therapies are often significantly limited in the human intestine by the metabolic activities of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Predicting whether candidate compounds induce CYP3A4 an
Publikováno v:
Biopharmaceutics & Drug Disposition; Apr2015, Vol. 36 Issue 3, p139-147, 9p